276 Journal of Medicinal Chemistry, 2011, Vol. 54, No. 1
Ioannidis et al.
(2) Levine, R. L.; Wadleigh, M.; Cools, J.; Ebert, B. L.; Wernig, G.;
Huntly, B. J. P.; Boggon, T. J.; Wlodarska, I.; Clark, J. J.; Moore,
S.; Adelsperger, J.; Koo, S.; Lee, J. C.; Gabriel, S.; Mercher, T.;
(14) Ioannidis, S.; Lamb, M. L.; Davies, A. M.; Almeida, L.; Su, M.;
Bebernitz, G.; Ye, M.; Bell, K.; Alimzhanov, M.; Zinda, M.
Discovery of pyrazol-3-ylamino pyrazines as novel JAK2 inhibi-
tors. Bioorg. Med. Chem. Lett. 2009, 19, 6524–6528. See also for the
use of high versus low ATP concentration Knight, A. Z.; Shokat, K. M.
Features of selective kinase inhibitors. Chem. Biol. 2005, 12, 621–637.
(15) Compound 9g displayed good activity in an EPOR Stat5 cellular
assay, EC50 = 0.039 mM. For more details about the assay see ref 16.
(16) Ioannidis, S.; Lamb, M. L.; Almeida, L.; Guan, H.; Peng, B.;
Bebernitz, G.; Bell, K.; Alimzhanov, M.; Zinda, M. Replacement
of pyrazol-3-yl amine hinge binder with thiazol-2-yl amine: Dis-
covery of potent and selective JAK2 inhibitors. Bioorg. Med.
Chem. Lett. 2010, 20, 1669–1673.
(17) Guan, H.; Hayter, B. R.; Huang, S.; Ioannidis, S.; Johannes, J.;
Lamb, M.; Peng, B.; Yang, B. Preparation of pyrazolyl-amino-
substituted pyrimidines and their use for the treatment of cancer.
WO2008132502, 2008.
(18) Boggon, T. J.; Li, Y.; Manley, P. W.; Eck, M. J. Crystal structure of
the Jak3 kinase domain in complex with a staurosporine analog.
Blood 2005, 106, 996–1002.
(19) Hedvat, M.; Huszar, D.; Herrmann, A.; Gozgit, J. M.; Schroeder,
A.; Sheehy, A.; Buettner, R.; Proia, D.; Kowolik, C. M.; Xin, H.;
Armstrong, B.; Bebernitz, G.; Weng, S.; Wang, L.; Ye, M.;
McEachern, K.; Chen, H.; Morosini, D.; Bell, K.; Alimzhanov,
M.; Ioannidis, S.; McCoon, P.; Cao, Z. A.; Yu, H.; Jove, R.; Zinda,
M. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling
and oncogenesis in solid tumors. Cancer Cell 2009, 16, 487–497.
(20) Mortlock, A. A.; Foote, K. M.; Heron, N. M.; Jung, F. H.;
Pasquet, G.; Lohmann, J-J. M.; Warin, N.; Renaud, F.; De Savi,
C.; Roberts, N. J.; Johnson, T.; Dousson, C. B.; Hill, G. B.;
Perkins, D.; Hatter, G.; Wilkinson, R. W.; Wedge, S. R.; Heaton,
S. P.; Odedra, R.; Keen, N. J.; Crafter, C.; Brown, E.; Thompson,
K.; Brightwell, S.; Khatri, L.; Brady, M. C.; Kearney, S.; McKillop,
D.; Rhead, S.; Parry, T.; Green, S. Discovery, synthesis, and in vivo
activity of a new class of pyrazolylamino quinazolines as selective
inhibitors of Aurora B Kinase. J. Med. Chem. 2007, 50, 2213–2224.
(21) Thress, K.; MacIntyre, T.; Wang, H.; Whitston, D.; Liu, Z.-Y.;
Hoffmann, E.; Wang, T.; Brown, J. L.; Webster, K.; Omer, C.;
Zage, P. E.; Zeng, L.; Zweidler-McKay, P. A. Identification and
preclinical characterization of AZ-23, a novel, selective, and orally
bioavailable inhibitor of the Trk kinase pathway. Mol. Cancer
Ther. 2009, 8, 1818–1827.
€
€
D’Andrea, A.; Frohling, S.; Dohner, K.; Marynen, P.; Vanden-
berghe, P.; Mesa, R. A.; Tefferi, A.; Griffin, J. D.; Eck, M. J.;
Sellers, W. R.; Meyerson, M.; Golub, T. R.; Lee, S. J.; Gilliland,
D. G. Activating mutation in the tyrosine kinase JAK2 in poly-
cythemia vera, essential thrombocythemia, and myeloid metapla-
sia with myelofibrosis. Cancer Cell 2005, 7, 387–397.
ꢀ
(3) James, C.; Ugo, V.; Le Couedic, J. P.; Staerk, J.; Delhommeau, F.;
Lacout, C.; Garc-on, L.; Raslova, H.; Berger, R.; Bennacaur-
Griscelli, A.; Villeval, J. L.; Constantinescu, S. N.; Casadevall,
N.; Vainchenker, W. A unique clonal JAK2 mutation leading to
constitutive signaling causes polycythemia vera. Nature 2005, 434,
1144–1148.
(4) Baxter, E. J.; Scott, L. M.; Campbell, P. J.; East, C.; Fourouclas,
N.; Swanton, S.; Vassiliou, G. S.; Bench, A. J.; Boyd, E. M.; Curtin,
N.; Scott, M. A.; Erber, W. N.; the Cancer Genome project; Green,
A. R. Acquired mutation of the tyrosine kinase JAK2 in human
myeloproliferative disorders. Lancet 2005, 365, 1054-1061.
(5) Levine, R. L. Mechanisms of mutations in myeloproliferative
neoplasms. Best Pract. Res. Clin. Haematol. 2009, 22, 489–494.
ꢀ
(6) Quintas-Cardama, A.; Vaddi, K.; Liu, P; Manshouri, T.; Li, J.;
Scherle, P. A.; Caulder, E.; Wen, X.; Li, Y.; Waeltz, P.; Rupar, M.;
Burn, T.; Lo, Y.; Kelley, J.; Covington, M.; Shepard, S.; Rodgers,
J. D.; Haley, P.; Kantarjian, H.; Fridman, J. S.; Verstovsek, S.
Preclinical characterization of the selective JAK1/2 inhibitor
INCB018424: therapeutic implications for the treatment of mye-
loproliferative neoplasms. Blood 2010, 115, 3109–3117.
(7) Wernig, G.; Kharas, M. G.; Okabe, R.; Moore, S. A.; Leeman,
D. S.; Cullen, D. E.; Gozo, M.; McDowell, E. P.; Levine, R. L.;
Doukas, J.; Mak, C. C.; Noronha, G.; Martin, M.; Ko, Y. D.; Lee,
B. H.; Soll, R. M.; Tefferi, A.; Hood, J. D.; Gilliland, D. G. Efficacy
of TG101348, a selective JAK2 inhibitor, in treatment of a murine
model of JAK2V617F-induced polycythemia vera. Cancer Cell
2008, 13, 311–320.
(8) Burns, C. J.; Bourke, D. G.; Andrau, L.; Bu, X.; Charman, S. A.;
Donohue, A. C.; Fantino, E.; Farrugia, M.; Feutrill, J. T.; Joffe,
M.; Kling, M. R.; Kurek, M.; Nero, T. L.; Nguyen, T.; Palmer,
J. T.; Phillips, I.; Shackleford, D. M.; Sikanyik, H.; Styles, M.; Su,
S.; Treutlein, H.; Zeng, J.; Wilks, A. F. Phenylaminopyrimidines as
inhibitors of Janus kinases (JAKs). Bioorg. Med. Chem. Lett. 2009,
19, 5887–5882.
(9) Hexner, E. O.; Serdikoff, C.; Jan, M.; Swider, C. R.; Robinson, C.;
Yang, S.; Angeles, T.; Emerson, S. G.; Carroll, M.; Ruggeri, B.;
Dobrzanski, P. Lestaurtinib (CEP701) is a JAK2 inhibitor that
suppresses JAK2/STAT5 signaling and the proliferation of pri-
mary erythroid cells from patients with myeloproliferative disor-
ders. Blood 2008, 111, 5663–5671.
(22) Quentmeier, H.; MacLeod, R. A.; Zaborski, M.; Drexler, H. G.
JAK2V617 tyrosine kinase mutation in cell lines derived from
myeloproliferative disorders. Leukemia 2006, 20, 471–476.
(23) Rehemtulla, A.; Stegman, L. D.; Cardozo, S. J.; Gupta, S.; Hall,
D. E.; Contag, C. H.; Brian D Ross, B. D. Rapid and quantitative
assessment of cancer treatment response using in vivo biolumines-
cence imaging. Neoplasia 2000, 2, 491–495.
(10) Plo, I.; Vaincheker, W. Molecular and genetic bases of myelopro-
liferative disorders: questions and perspectives. Clin. Lymphoma,
Myeloma Leukemia 2009, 9 (Suppl.3), S329–S339.
(11) Wang, T.; Lamb, M. L.; Scott, D. A.; Wang, H.; Block, M. H.;
Lyne, P. D.; Lee, J. W.; Davies, A. M.; Zhang, H.; Zhu, Y.; Gu, F.;
Han, Y.; Wang, B.; Mohr, P. J.; Kaus, R. J.; Josey, J. A.;
Hoffmann, E.; Thress, K.; MacIntyre, T.; Wang, H.; Omer,
C. A.; Yu, D. Identification of 4-aminopyrazolylpyrimidines as
potent inhibitors of Trk kinases. J. Med. Chem. 2008, 51, 4672–
4684.
(24) QUANTA, Release 2000, San Diego: Accelrys Inc., 2000.
(25) Collaborative Computational Project Number 4. The CCP4 suite:
programs for protein crystallography. Acta Crystallogr. 1994, D50,
760–763.
(26) Lucet, I. S.; Fantino, E.; Styles, M.; Bamert, R.; Patel, O.; Brought-
on, S. E.; Walter, M.; Burns, C. J.; Treutlein, H.; Wilks, A. F.;
Rossjohn, J. The structural basis of Janus kinase 2 inhibition by a
potent and specific pan-Janus kinase inhibitor. Blood 2006, 107,
176–183.
(27) COOT: Emsley, P.; Lohkamp, B.; Scott, W.; Cowtan, K. Acta
(12) Baasner, B.; Klauke, E. A new route to the synthesis of 5-fluoro-
Crystallogr. 2010, D66, 486-501.
uracil. J. Fluorine Chem. 1989, 45, 417–430.
(28) AFITT: OpenEye Scientific Software, Inc., Santa Fe, NM, USA,
(13) Gozgit, J. M.; Bebernitz, G.; Patil, P.; Ye, M.; Wu, J.; Su, N.;
Wang, T.; Ioannidis, S.; Davies, A. M.; Huszar, D.; Zinda, M.
Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL
survival signaling in the human JAK2 V617F cell line SET-2.
J. Biol. Chem. 2008, 283, 32334–32343.
(29) Refmac v 5.1.17: Murshudov, G. N.; Vagin, A. A.; Dodson, E. J.
Acta Crystallogr. 1997, D53, 240-255.
(30) DeLano, W. L. The PyMOL molecular graphics system; DeLano